Clinical Trial Update: 12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation. [Phase 2]

View source ↗

Summary

Pfizer reports Phase 2 results evaluating four dosing regimens of CP-526,555 versus placebo for smoking cessation over 12 weeks, focusing on safety and efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• CP-526,555

Snippet

Sponsor: Pfizer | Conditions: Smoking Cessation | Phase 2 | Status: COMPLETED